Brief: Astrazeneca Pharma India Ltd Receives Permission To Import Durvalumab
10/02/2026 05:41
Feb 10 (Reuters) - Astrazeneca Pharma India Ltd ASTR.NS: ASTRAZENECA PHARMA INDIA LTD - RECEIVES PERMISSION TO IMPORT DURVALUMAB ASTRAZENECA PHARMA - PERMISSION PAVES WAY FOR MARKETING OF DURVALUMAB SOLUTION IN INDIA Source text: ID:nBSE4kw3HB Further company coverage: ASTR.NS ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Astrazeneca Pharma India
See all newsBrief: Astrazeneca Pharma Gets Permission To Import For Sale Of Trastuzumab Deruxtecan
India's Astrazeneca Pharma logs worst slide in two months on quarterly profit drop
Brief: Astrazeneca Pharma India March-Quarter PAT 448.8 Million Rupees
Brief: Astrazeneca Pharma India Recommends Dividend Of 36 Rupees Per Equity Share For Fy2025-26
Brief: Astrazeneca Pharma India Receives Permission To Import Durvalumab (Imfinzi) For Additional Indication